| __timestamp | Amicus Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 72471000 |
| Thursday, January 1, 2015 | 47269000 | 89204000 |
| Friday, January 1, 2016 | 71151000 | 106010000 |
| Sunday, January 1, 2017 | 88671000 | 137905000 |
| Monday, January 1, 2018 | 127200000 | 159888000 |
| Tuesday, January 1, 2019 | 169861000 | 158425000 |
| Wednesday, January 1, 2020 | 156407000 | 200677000 |
| Friday, January 1, 2021 | 192710000 | 304759000 |
| Saturday, January 1, 2022 | 213041000 | 377221000 |
| Sunday, January 1, 2023 | 275270000 | 336361000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Amicus Therapeutics and Supernus Pharmaceuticals from 2014 to 2023. Over this period, Amicus Therapeutics saw a staggering increase of over 1,200% in SG&A expenses, starting from approximately $20 million in 2014 to nearly $275 million in 2023. Meanwhile, Supernus Pharmaceuticals experienced a 364% rise, with expenses growing from about $72 million to $336 million. This trend highlights the aggressive expansion and operational scaling both companies have undertaken. Notably, Supernus consistently outspent Amicus, reflecting its broader market reach and strategic investments. These insights provide a window into the financial strategies driving growth in the biotech sector, underscoring the importance of SG&A management in sustaining competitive advantage.
Comparing SG&A Expenses: Merck & Co., Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Incyte Corporation and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
ADMA Biologics, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Amicus Therapeutics, Inc. or Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Supernus Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends